MedPage Today on MSN
FDA Proposes More Flexibility in Alternatives to Animal Testing in Drug Development
Non-animal testing methods could save drugmakers time and money, officials say ...
FDA’s NAM framework emphasizes context of use, human biological relevance, technical characterization, and fit-for-purpose ...
Morning Overview on MSN
FDA urges alternatives to animal testing in early-stage drug development
The U.S. Food and Drug Administration is actively steering drug developers away from traditional animal studies and toward ...
The U.S. Food and Drug Administration announced Thursday that it will be phasing out a requirement that monoclonal antibodies and other drugs be tested on animals, saying in a news release that there ...
Early 2026 has brought a series of consequential regulatory moves from the FDA, each reflecting a common thread: the agency ...
In this chapter, we focus on two topics: the lack of enforcement of existing U.S. Department of Defense (DOD) guidelines and procedures and the role of the program manager in the acquisition process.
In April 2025, the FDA announced plans to shift biomedical research for monoclonal antibodies and other medications away from ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results